Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5278505 | 0.84 | — | — | |
| SCHEMBL5281901 | 0.83 | ALDH1A1 (0.30) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL26214423 | 0.82 | — | — | |
| SCHEMBL5278616 | 0.81 | MAOB (0.31) | — | |
| SCHEMBL5284488 | 0.79 | — | — | |
| SCHEMBL5273356 | 0.77 | GRIA1 (0.33) | — | |
| SCHEMBL5281595 | 0.77 | GABRB3 (0.35) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL5277554 | 0.77 | GABRB3 (0.35) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL5281341 | 0.75 | ALDH1A1 (0.31) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL5275884 | 0.75 | GRIA1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230045277-A1 | COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-10844090-B2 | Hemiasterlin derivatives for conjugation and therapy | SUTRO BIOPHARMA, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| EP-1859781-A2 | Brightening and/or colouring agent with triazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844090-B2 | Hemiasterlin derivatives for conjugation and therapy | CYP17A1, HSD17B7, SHBG | ALDH1A1 1882/4885CYP1A2 776/4885CYP2C19 2167/4885 |
| US-20230045277-A1 | COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF | PAH, BMP2, COL2A1 | ALDH1A1 1058/4885CYP1A2 361/4885CYP2C19 82/4885 |
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | ZFX, XPA, CTCF | ALDH1A1 1825/4885CYP1A2 3887/4885CYP2C19 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.